Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

NCT06648031 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of DehydraTECH-CBD and DehydraTECH-GLP1 agonists, alone or together, in adults who are overweight, obese, or have type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 148 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-12 · est. completion 2025-07

Where 7 sites · Australia

What this study is testing ClinicalTrials.gov NCT06648031 ↗

Description as written by the study sponsor.

This is a Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics and efficacy of DehydraTECH Cannabidiol and Glucagon-like Peptide 1 (GLP-1) agonists alone and in combination, in overweight or obese, pre- and type 2 diabetic participants.

Treatments tested

Arm 1 - DehydraTECH-CBD alone Drug

Dose: 250 mg CBD twice daily (500 mg/day) for 12 weeks. Route of administration: Oral Dosage form: Capsule
Arm 2 - DehydraTECH-semaglutide alone Drug

Dose: 3.5 mg once daily for 4 weeks, ascending to 7 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide Drug

DehydraTECH-CBD dosing = 250 mg twice daily for 12 weeks. \- DehydraTECH-semaglutide = 3.5 mg once daily for 12 weeks Route of administration: Oral Dosage form: Capsule
Arm 4 - Rybelsus medication (semaglutide) alone Drug

Normal clinical dose of 3.0 mg once daily for 4 weeks, ascending to 7.0 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule
Arm 5- Tirzepatide Drug

Tirzepatide arm - 20mg for 4 weeks and then 40mg for 8 weeks

Main thing measured	Number of participants with treatment-emergent adverse events (TEAEs) and Serious adverse events
Sponsor	Lexaria Bioscience Corp.
Conditions studied	Type2diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06648031 ↗